Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (561-570 of 595) with videos related to

Pageof 60
Sort By:
Leukemia|October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st studyA Hochhaus, G Rosti, N C P Cross, et al.
Blood|February 21, 2012
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesFrederik Damm, Olivier Kosmider, Véronique Gelsi-Boyer, et al.
Annals of Hematology|July 21, 2017
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phaseMohamad Jawhar, Nicole Naumann, Juliana Schwaab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2019
MARS: Mutation-Adjusted Risk Score for Advanced Systemic MastocytosisMohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Regulatory Toxicology and Pharmacology : RTP|February 17, 2016
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicityErnst Ahlberg, Alexander Amberg, Lisa D Beilke, et al.
Computational Toxicology (Amsterdam, Netherlands)|March 28, 2022
<i>In silico</i> approaches in organ toxicity hazard assessment: current status and future needs in predicting liver toxicityArianna Bassan, Vinicius M Alves, Alexander Amberg, et al.
Mutagenesis|October 26, 2018
Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge ProjectMasamitsu Honma, Airi Kitazawa, Alex Cayley, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|May 21, 2010
Survey of medical training in cytopathology carried out by the journal CytopathologyAnshu, A Herbert, B Cochand-Priollet, et al.
American Journal of Human Genetics|January 9, 2021
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosisGabriella Galatà, Andrés C García-Montero, Thomas Kristensen, et al.
Pageof 60

Showing results (561-570 of 595) with videos related to

Sort By:
Pageof 60
Leukemia|October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st studyA Hochhaus, G Rosti, N C P Cross, et al.
Blood|February 21, 2012
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesFrederik Damm, Olivier Kosmider, Véronique Gelsi-Boyer, et al.
Annals of Hematology|July 21, 2017
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phaseMohamad Jawhar, Nicole Naumann, Juliana Schwaab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2019
MARS: Mutation-Adjusted Risk Score for Advanced Systemic MastocytosisMohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Regulatory Toxicology and Pharmacology : RTP|February 17, 2016
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicityErnst Ahlberg, Alexander Amberg, Lisa D Beilke, et al.
Computational Toxicology (Amsterdam, Netherlands)|March 28, 2022
<i>In silico</i> approaches in organ toxicity hazard assessment: current status and future needs in predicting liver toxicityArianna Bassan, Vinicius M Alves, Alexander Amberg, et al.
Mutagenesis|October 26, 2018
Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge ProjectMasamitsu Honma, Airi Kitazawa, Alex Cayley, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|May 21, 2010
Survey of medical training in cytopathology carried out by the journal CytopathologyAnshu, A Herbert, B Cochand-Priollet, et al.
American Journal of Human Genetics|January 9, 2021
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosisGabriella Galatà, Andrés C García-Montero, Thomas Kristensen, et al.
Pageof 60